3,500,000 Shares Keros Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 4th, 2024 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • April 1st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 2020 between Keros Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
Keros Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20__ Debt SecuritiesIndenture • May 3rd, 2021 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [], 20__, among Keros Therapeutics, Inc., a Delaware corporation (the “Company”), and[TRUSTEE], as trustee (the “Trustee”):
KEROS THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • May 3rd, 2021 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between KEROS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
Keros Therapeutics, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • May 3rd, 2021 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
Keros Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
KEROS THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • May 3rd, 2021 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between KEROS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 21st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of November, 2018, by and among Keros Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
KEROS THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2017 Stock Incentive PlanIncentive Stock Option Agreement • March 16th, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 16th, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 2nd day of March, 2020, by and among Keros Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • January 31st, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), by and between Keros Therapeutics, Inc. (the “Company”), and Christopher Rovaldi (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), is effective as of February 1, 2022 (the “Effective Date”).
Page ARTICLE 1: BASIC TERMS 1 ARTICLE 2: PREMISES AND APPURTENANT RIGHTS 4 2.01 Lease of Premises; Appurtenant Rights 4 2.02 Roof License 6 ARTICLE 3: LEASE TERM 8 3.01 Lease Term 8 3.02 Hold Over 9 3.03 Right to Extend 9 ARTICLE 4: RENT 11 4.01 Base...Lease • March 16th, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations
1050 WALTHAM STREET LEXINGTON, MASSACHUSETTS Lease to KEROS THERAPEUTICS INC. FROM THE OFFICE OF: Goulston & Storrs PC 400 Atlantic Avenue Boston, Massachusetts 02110-3333Indenture of Lease • November 4th, 2021 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS INDENTURE OF LEASE (this “Lease”) made as of the 7th day of September, 2021 (the “Effective Date”), by and between Revolution Labs Owner, LLC, a Delaware limited liability company, having a mailing address c/o Greatland Realty Partners, One Federal Street, 18th Floor, Boston, Massachusetts 02110 (hereinafter referred to as the “Landlord”), of the one part, and the tenant named in Section 1.1(a) below (hereinafter referred to as the “Tenant”), of the other part.
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: [***] MGH Case Nos: [***]Patent License Agreement • March 16th, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This License Agreement (“Agreement”) is made as of the 5th day of April, 2016 (“Effective Date”), by and between Keros Therapeutics, Inc., a Delaware corporation, having a principal place of business at 3 Lincoln Terrace, Lexington, MA 02421 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT BETWEEN KEROS THERAPEUTICS, INC. AND NOVO NORDISK A/SResearch Collaboration and Exclusive License Agreement • March 16th, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Exclusive License Agreement (“Agreement”) is made and entered into, effective as of December 14, 2017 (“Effective Date”), by and between Keros Therapeutics, Inc., a Delaware corporation, having a principal place of business at Suite 120, Building E, 99 Hayden Avenue, Lexington, MA 02421, USA (“Keros”) and Novo Nordisk A/S, a company organized and existing under the laws of Denmark, having a principal place of business at Novo Allé, DK-2880 Bagsværd, Denmark (“Novo Nordisk”). Keros and Novo Nordisk are each referred to herein individually as a “Party” and collectively as the “Parties”.
ContractKeros Therapeutics, Inc. • November 3rd, 2022 • Pharmaceutical preparations
As discussed, and at your request, this offer letter agreement (the “Agreement”) sets forth the revised terms and conditions of your employment with Keros Therapeutics, Inc. (the “Company”). These terms shall go into on September 1, 2022 (the “Effective Date”), at which time they shall supersede and replace the terms of the Executive Employment Agreement entered into by you and the Company as of March 16, 2020, as amended by that certain amendment dated January 1, 2022 (the “Prior Employment Agreement”).
AMENDMENT NO. 2 TO LICENSE AGREEMENTLicense Agreement • March 3rd, 2023 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 2 (this “Amendment”) is entered into as of March 11, 2022 (the “Amendment Effective Date”), by and between KEROS THERAPEUTICS, INC., corporation organized and existing under the laws of Delaware and having a place of business at 99 Hayden Avenue, Suite 120, Building E, Lexington, MA 02421 (“Keros”), and HANSOH (SHANGHAI) HEALTHTECH CO., LTD., a corporation organized and existing under the laws of the People’s Republic of China having a place of business at Room 101, No.287 Xiangke Road and No.1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh”). Keros and Hansoh are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is entered into as of February 10, 2022 (the “Amendment Effective Date”), by and between Keros Therapeutics, Inc., corporation organized and existing under the laws of Delaware and having a place of business at 99 Hayden Avenue, Suite 120, Building E, Lexington, MA 02421 (“Keros”), and Hansoh (Shanghai) Healthtech Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China having a place of business at Room 101, No.287 Xiangke Road and No.1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh”). Keros and Hansoh are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF SIMON COOPEREmployment Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to the Executive Employment Agreement of Simon Cooper the (“Amendment”) is entered into this 1st day of January, 2022 (the “Effective Date”), by and between Simon Cooper (the “Executive”) and Keros Therapeutics, Inc. (the “Company”).
FIRST AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF JENNIFER LACHEYEmployment Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to the Executive Employment Agreement of Jennifer Lachey the (“Amendment”) is entered into this 1st day of January, 2022 (the “Effective Date”), by and between Jennifer Lachey (the “Executive”) and Keros Therapeutics, Inc. (the “Company”).
KEROS THERAPEUTICS, INC. Lexington, Massachusetts 02421Consulting Agreement • August 2nd, 2021 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This letter sets forth the substance of the separation and release agreement (the “Agreement”) which Keros Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
FIRST AMENDMENT TO LEASELease • May 4th, 2023 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE (this “Amendment”) is made as of this 6th day of January, 2023 (the “Execution Date”) by and between REVOLUTION LABS OWNER, LLC, a Delaware limited liability company (“Landlord”), and KEROS THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF KEITH REGNANTEEmployment Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to the Executive Employment Agreement of Keith Regnante the (“Amendment”) is entered into this 1st day of January, 2022 (the “Effective Date”), by and between Keith Regnante (the “Executive”) and Keros Therapeutics, Inc. (the “Company”).
AMENDMENT NO. 4 TO LICENSE AGREEMENTLicense Agreement • February 28th, 2024 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 4 (this “Amendment”) is entered into as of April 12, 2023 (the “Amendment Effective Date”), by and between KEROS THERAPEUTICS, INC., corporation organized and existing under the laws of Delaware and having a place of business at 1050 Waltham Street, Suite 302, Lexington, MA 02421 (“Keros”), and HANSOH (SHANGHAI) HEALTHTECH CO., LTD., a corporation organized and existing under the laws of the People’s Republic of China having a place of business at Room 101, No.287 Xiangke Road and No.1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh”). Keros and Hansoh are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LEDGEMONT TECHNOLOGY CENTER Lexington, Massachusetts THIRD AMENDMENT TO LEASE KEROS THERAPEUTICS, INC.Keros Therapeutics, Inc. • August 5th, 2021 • Pharmaceutical preparations • Massachusetts
Third Amendment to Lease (“Third Amendment”) dated as of August 4, 2021 between 99 Hayden LLC, a Delaware limited liability company, successor-in-interest to 128 Spring Street Lexington, LLC, a Delaware limited liability company (“Landlord”), and Keros Therapeutics, Inc. a Delaware corporation (“Tenant”).
